ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Deficiency of Antibody-Suppressor CXCR5+CD8+ T Cells (Not CD4+ Tregs) Drive High Alloantibody Production in CCR5 KO Kidney Transplant Recipients

J. L. Han1, J. M. Zimmerer1, Q. Zeng2, S. Chaudhari1, C. K. Breuer2, G. L. Bumgardner1

1Dept of Surgery, The Ohio State University, Columbus, OH, 2Center for Regen. Med., The Research Institute at Nationwide Children's Hospital, Columbus, OH

Meeting: 2022 American Transplant Congress

Abstract number: 1253

Keywords: B cells, Effector mechanisms, T cells

Topic: Basic Science » Basic Science » 10 - Treg/Other Regulatory Cell/Tolerance

Session Information

Session Name: Treg/Other Regulatory Cell/Tolerance

Session Type: Poster Abstract

Date: Monday, June 6, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Kidney transplant (KTx) into CCR5 KO mice is an excellent model to study AMR immunobiology due to high alloantibody (alloAb) production, rapid allograft rejection, and pathology consistent with human AMR. A proposed mechanism for this heightened humoral response is impaired CD4+Treg cell trafficking to the allograft. We have previously observed that adoptive cell therapy (ACT) with CXCR5+CD8+T cells mediates significant reduction of alloAb titer after KTx in CCR5 KO mice. We hypothesized that CXCR5+CD8+T cells are more potent regulators of alloAb production compared to CD4+Tregs.

*Methods: WT and KO mice (H-2b) underwent allogeneic KTx (A/J; H-2a). Recipients underwent ACT with 2*106 CXCR5+CD8+T cells or CD25+CD4+Tregs. Cohorts of WT mice were treated with either anti-CD8 or anti-CD25 mAbs. AlloAb titer and immune cell subsets were analyzed by flow cytometry on postTx day 14.

*Results: CCR5 KO recipients have significantly higher alloAb titer (5951±630) compared to WT (1508±145; p<0.001). KO recipients have significantly fewer CXCR5+CD8+T cells (782±183 vs 2058±167 cells/mm3; p<0.0001) and graft-infiltrating CD4+Treg cells (CD25+FoxP3+; 12.9±8.8 vs 56.2±8.8 cells/mm3; p=0.003) compared to WT recipients. KO compared to WT recipients have significantly greater quantity of splenic IL-21+CXCR5+PD1+CD4+TFH cells (331±34 vs 36±44 cells/mm3) and germinal center (GC; GL7+Fas+B220+) B cells (5814±436 vs 671±342 cells/mm3; both p<0.0001). AlloAb titer in KO recipients is significantly reduced following ACT with alloprimed CXCR5+CD8+T cells (1259±436 vs 5951±404 in untreated controls; p<0.0001) but not following CD4+ACT (5688±436; p=ns). ACT with CXCR5+CD8+T cells reduced the quantity of splenic IL-21+TFH cells (from 331±34 in untreated controls to 66±31 cells/mm3; p<0.0001) and GC B cells (from 5813±589 in untreated controls to 4087±537; p=0.002), while CD4+Treg ACT had no impact (IL-21+TFH: 241±36 cells and GC B cells: 6916±538/mm3; p=ns for both). Compared to untreated controls, CD8-depletion in WT recipients led to significant increase in alloAb titer (1508±338 vs 6078±436; p<0.001) and GC B cells (671±436 vs 7761±430; p<0.0001). CD4+Treg depletion resulted in increased alloAb titer (3180±436; p=0.004) and GC B cell quantity (4911±429; p<0.0001), however, these increases were less pronounced than in the CD8-depleted group (p<0.001 for both).

*Conclusions: CCR5 KO KTx recipients are deficient in CXCR5+CD8+T cells and graft-infiltrating CD4+Treg cells, which is associated with heightened humoral alloimmunity. This is rescued following ACT of CXCR5+CD8+ T cells but not CD4+Tregs, suggesting that Ab-suppressor CXCR5+CD8+ T cells are more potent regulators of antibody production than CD4+Tregs.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Han JL, Zimmerer JM, Zeng Q, Chaudhari S, Breuer CK, Bumgardner GL. Deficiency of Antibody-Suppressor CXCR5+CD8+ T Cells (Not CD4+ Tregs) Drive High Alloantibody Production in CCR5 KO Kidney Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/deficiency-of-antibody-suppressor-cxcr5cd8-t-cells-not-cd4-tregs-drive-high-alloantibody-production-in-ccr5-ko-kidney-transplant-recipients/. Accessed May 17, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences